Order Skyrizi (risankizumab-rzaa) bulk order online

Order Skyrizi Online

Skyrizi is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment

Order Skyrizi Online

Order Skyrizi Online

Skyrizi is a prescription medicine used to treat moderate to severe plaque psoriasis in adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet or UV light) treatment. Skyrizi is also used to treat active psoriatic arthritis and moderate to severe Crohn's disease. Skyrizi contains risankizumab-rzaa, a monoclonal antibody that targets a protein in the body called interleukin-23 (IL-23), helping to reduce inflammation.

About Skyrizi

Skyrizi is an injectable solution that provides targeted relief for several chronic inflammatory conditions. Administered under the skin, it is typically given once every 12 weeks after the initial two starter doses. It is critical to follow your healthcare provider's instructions and complete the full course of medication to experience optimal results.

Company Description

Skyrizi is developed and marketed by AbbVie, a global biopharmaceutical company with a focus on science-driven healthcare innovation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

Product Images

These images provide an accurate representation of Skyrizi packaging and appearance. Please ensure you confirm packaging with authorized sources before making any decisions regarding your medication.

Order Skyrizi (risankizumab-rzaa) Online Order Skyrizi (risankizumab-rzaa) Online

Skyrizi (risankizumab-rzaa) is an FDA-approved prescription medicine used to treat moderate to severe plaque psoriasis in adults who may benefit from taking injections or other systemic therapies. Skyrizi helps relieve symptoms such as scaling, redness, and itching by targeting the source of inflammation in the body and working to block a specific protein (interleukin-23) involved in the immune system response that causes psoriasis.

About Skyrizi (risankizumab-rzaa)

Skyrizi is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively block interleukin 23 (IL-23) by binding to its p19 subunit. This helps to reduce inflammation in individuals with plaque psoriasis. The treatment is administered as a subcutaneous injection, typically once every 12 weeks after two starter doses at weeks 0 and 4. It is a long-acting medication with demonstrated effectiveness in clinical studies showing significant improvement in skin clearance and quality of life for patients. Skyrizi is manufactured using recombinant DNA technology in Chinese hamster ovary cells.